No black box warning on record for Hyrnuo

As of the latest FDA labeling reviewed, Hyrnuo (SEVABERTINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Hyrnuo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Diarrhea : At the first sign of diarrhea or increased bowel movement frequency, instruct patients to start an antidiarrheal treatment, and to increase their fluid and electrolyte intake. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity. ( 5.1 ) Hepatotoxicity : Monitor liver function tests including ALT, AST, and total bilirubin at baseline

No black box warning on record for Hyrnuo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Diarrhea : At the first sign of diarrhea or increased bowel movement frequency, instruct patients to start an antidiarrheal treatment, and to increase their fluid and electrolyte intake. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity. ( 5.1 ) Hepatotoxicity : Monitor liver function tests including ALT, AST, and total bilirubin at baseline

Hyrnuo Black Box Warning

No black box warning on record for Hyrnuo

Other warnings & precautions

Hyrnuo Black Box Warning

No black box warning on record for Hyrnuo

Other warnings & precautions